<DOC>
	<DOCNO>NCT01441804</DOCNO>
	<brief_summary>Patients HCV genotype 1 IL28B CC Polymorphism rapid virological response treatment randomise either 24 48 week HCV treatment . Our hypothesis important difference effect two treatment effect .</brief_summary>
	<brief_title>A Randomized Trial 24-Week Versus 48-Week Courses Peginterferon Plus Ribavirin Patients With Genotype 1 Hepatitis C IL28B CC Polymorphism</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Age &gt; 18 year Serum Hepatitis C RNA &gt; 10,000IU/mL Hepatitis C virus genotype 1 IL28B CC polymorphism Previous treatment chronic Hepatitis C clinical biological evidence acute hepatitis , include serum ALT AST &gt; 300U/ml HIV antibody positive , hepatitis b surface antigen positive know diagnosis chronic liver disease Contraindications PRbased treatment : Uncontrolled psychiatric illness Active substance dependency Known autoimmune disorder Untreated thyroid disease Uncontrolled seizure disorder Pregnancy , lactation inability maintain contraception Chronic kidney disease w/ estimate GFR &lt; 60 ANC &lt; 1.5/nl , Hb &lt; 12g/dl , platelet &lt; 75/nl Clinical biochemical evidence decompensated liver disease include : History encephalopathy Ascites Variceal bleed Bilirubin &gt; 3g/dl INR &gt; 1.5 Life threaten disorder expect median survival le 5 year Inability comply drug regimen test schedule require study</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>